BioStem Technologies, Inc. (BSEM) analyst actions
Rating and price-target actions on BSEM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BSEM overview →
2 measured BSEM analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions | Press release | +0.42% | +17.49% | |
| BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers | Press release | +0.00% | -3.00% |
Keep exploring
More BSEM: earnings → · SEC filings → · BSEM overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Fonar Corporation (FONR) | 137 | 0.00% | 34% |
| Biomerica, Inc. (BMRA) | 135 | 0.00% | 49% |
| Amedisys Inc (AMED) | 134 | -0.01% | 44% |
| ISODIOL INTERNATIONAL INC (ISOLF) | 134 | +0.20% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.